Life work culminates in testing of cancer therapy in humans

March 24, 2011

A cancer-fighting antibody identified by a researcher working at The University of Queensland and Queensland Institute of Medical Research (QIMR) will today be used to treat the first patient, in a Phase 1 clinical trial.

The trial is the culmination of many years work for Professor Andrew Boyd, Professor of Experimental Haematology at The University of Queensland and Head of QIMR's Leukaemia Foundation Laboratory.

Phase I have commenced using antibody KB004.

Phase 1 trials are the first step in a systematic process to determine if a drug might be efficacious in humans.

The monoclonal antibody has been shown to kill certain types of cancerous tumours ex vivo, that is in a laboratory using using human samples.

It is targeted towards EphA3 expressing , which are believed to account for about 50% of acute leukaemias as well as a number of other human cancers including a significant proportion of malignant melanomas, brain tumours and lung cancers.

Professor Boyd said the journey from the initial identification of the antibody to the stage of clinical testing has been long but very rewarding.

“The KB004 project has a special place in my heart as it originated in my own lab many years ago," Professor Boyd said.

"Although it now involves two other research groups in Australia and a U.S. company, there is a sense of nearing the goal I set out to achieve when I first started my research career.”

KaloBios Pharmaceuticals, a South San Francisco biotech company took the original mouse antibody and through a process known as Humaneering(TM) technology, developed an antibody that could be used in humans as it would be more likely to be tolerated by the human immune system.

“The initiation of a Phase I clinical trial in patients with acute leukaemia by KaloBios is an important landmark and will hopefully lead to further testing and the ultimate use of this antibody as a treatment," he said.

“As Leukaemia Foundation Professor of Experimental Haematology at The University of Queensland and a consultant Haematologist at the Royal Brisbane Hospital, it is highly significant to me that the phase I trial is in leukaemia, the disease that drove me to the initial discovery.

“I was motivated to enter research by the hope that I might do something which improved the lot of all patients with and related diseases – this is an immensely gratifying event.”

The antibody works by targeting a receptor protein found thus far in cancer cells and not on normal white blood cells or normal stem cells. It is hoped it will be well tolerated in patients with little or no side effects.

The development of this antibody as anti-cancer therapeutic was a collaboration between Professor Boyd, Professor Andrew Scott from the Ludwig Institute and Associate Professor Martin Lackmann from Monash University, who initiated and led the translational aspects of this venture.

Related Stories

Recommended for you

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Fundamental research enhances understanding of major cancer gene

October 19, 2017
New research represents a promising step towards better understanding of a key cancer gene. A long-running collaboration between researchers at the Babraham Institute, Cambridge and the AstraZeneca IMED Biotech Unit reveals ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

Mutant gene found to fuel cancer-promoting effects of inflammation

October 19, 2017
A human gene called p53, which is commonly known as the "guardian of the genome," is widely known to combat the formation and progression of tumors. Yet, mutant forms of p53 have been linked to more cases of human cancer ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.